Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exploratory Analysis of PTEN Deficiency by Immunohistochemistry from the Phase III CAPItello-291 Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research - 14 Aug 2026

Jhaveri Komal, Rugo Hope S, Cortés Javier, Oliveira Mafalda, Howell Sacha J, Dalenc Florence, Gomez Henry L, Hu Xichun, Krivorotko Petr, Loibl Sibylle, Okera Meena, Park Yeon Hee, Sohn Joohyuk, Toi Masakazu, Tokunaga Eriko, Zhukova Lyudmila, Nardone Agostina, Wadsworth Ian, D'Cruz Celina, Wantenaar Tanya, Das Dimple, de Bruin Elza C, Turner Nicholas C

Abstract excerpt

PURPOSE: The phosphoinositide 3-kinase (PI3K)/AKT serine/threonine kinase (AKT) pathway is frequently activated in hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, with loss of phosphatase and tensin homolog (PTEN) activity contributing to this activation. Capivasertib is a potent pan-AKT inhibitor, approved in combination with fulvestrant for the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Class I Phosphatidylinositol 3-Kinases

Share to Fulvestrant

Share to Immunohistochemistry

Share to Proto-Oncogene Proteins c-akt

Share to PTEN Phosphohydrolase

Share to Pyrimidines

Share to Pyrroles

Source

Open in PubMed Open full text

Identifiers

PMID: 42154572
DOI: 10.1158/1078-0432.CCR-25-2965
PMCID: PMC13473863

Genes

PTEN
AKT1
PIK3CA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exploratory Analysis of PTEN Deficiency by Immunohistochemistry from the Phase III CAPItello-291 Trial.PMID 42154572Read ↗

Clinicogenomic Landscape and Function of PIK3CA, AKT1, and PTEN Mutations in Breast Cancer.Semantic proximity Read ↗

Retrospective comparison between breast cancer tissue- and blood-based next-generation sequencing results in detection of PIK3CA, AKT1, and PTEN alterationsSemantic proximity Read ↗

New Emerging Therapies Targeting PI3K/AKT/mTOR/PTEN Pathway in Hormonal Receptor-Positive and HER2-Negative Breast Cancer—Current State and Molecular Pathology PerspectiveSemantic proximity Read ↗

Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.Semantic proximity Read ↗

Pan-cancer genomic analysis shows hemizygous PTEN loss tumors are associated with immune evasion and poor outcomeSemantic proximity Read ↗

"The emerging role of capivasertib in breast cancer".Semantic proximity Read ↗

Comprehensive Molecular and Genomic Analysis of NCI-MATCH Subprotocol Y: Capivasertib in Patients With an AKT1 E17K-Mutated Tumor.Semantic proximity Read ↗

Navigating the complexity of PI3K/AKT pathway in HER-2 negative breast cancer: biomarkers and beyondSemantic proximity Read ↗

Pan-cancer genomic analysis shows hemizygous <i>PTEN</i> loss tumors are associated with immune evasion and poor outcomeSemantic proximity Read ↗

Therapeutic targeting of cancers with loss of PTEN function.Semantic proximity Read ↗

Next-generation sequencing methodologies to identify patients for targeted therapy: focus on HR+/HER2- metastatic breast cancer.Semantic proximity Read ↗

mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of PIK3CA-Altered Tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.